scispace - formally typeset
D

Dong Wan Kim

Researcher at Seoul National University Hospital

Publications -  880
Citations -  61091

Dong Wan Kim is an academic researcher from Seoul National University Hospital. The author has contributed to research in topics: Lung cancer & Crizotinib. The author has an hindex of 89, co-authored 833 publications receiving 49632 citations. Previous affiliations of Dong Wan Kim include University of California, Irvine & Korea University.

Papers
More filters
Journal ArticleDOI

Clinical Course of Neuroendocrine Tumors With Different Origins (the Pancreas, Gastrointestinal Tract, and Lung)

Su Jung Kim, +9 more
- 01 Dec 2012 - 
TL;DR: Neuroendocrine tumors from the pancreas, GI tract, and lung showed different clinical characteristics, and stage, grade, and age were prognostic for overall survival (OS) and sex were prognosis for disease-free survival.
Journal ArticleDOI

MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics

Dohee Kwon, +11 more
- 01 Apr 2017 - 
TL;DR: MET-mutated NSCLC is characterized by older age and by an acinar histology and variable MET expression in patients with adenocarcinoma and pleomorphic carcinomas and the correlation among mutations, protein expression, and gene copy number of MET remain unclear.
Journal ArticleDOI

Highly stable sodium storage in 3-D gradational Sb-NiSb-Ni heterostructures

Chan Woo Lee, +4 more
- 01 Jul 2015 - 
TL;DR: In this paper, a compositionally gradational heterostructure composed of a Ni core, NiSb interface, and attached Sb crystals via pulsed electrodeposition under controlled conditions was realized.
Journal ArticleDOI

Pulmonary persistence of graphene nanoplatelets may disturb physiological and immunological homeostasis

Eun-Jung Park, +6 more
- 01 Mar 2017 - 
TL;DR: It is suggested that the long persistence of GNP in the lung may cause adverse health effects by disturbing immunological‐ and physiological‐homeostasis of the authors' body.
Journal ArticleDOI

Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations.

Yusoo Lee, +12 more
- 01 Sep 2019 - 
TL;DR: Osimertinib is active against EGFR exon 20 insertion-mutant NSCLC and flexibly binds within drug-binding pockets in preclinical models and the IC50 ratios for mutant to wild-type cells were higher than those for third-generation EGFR TKIs.